Marksans Pharma Ltd's Q2FY17 consolidated net profit declines 98.66% yoy to Rs.0.48 crore : Misses Estimates

India Infoline Research Team | November 12, 2016 15:11 IST

Marksans Pharma Ltd Q2FY17

Consolidated Results Q2FY17: (Rs. in crore)

Q2FY17 YoY (%)
Revenue 187.13 [26.8]
EBITDA 6.47 [87.4]
EBITDA Margin (%) 3.5 [1,665]
Net Profit (adjusted) 0.48 [98.7]
***EBITDA margin change is bps

Marksans Pharma Ltd’s Q2FY17 consolidated numbers misses Bloomberg estimates. Revenue for the period came in 10.9% below estimate of Rs 210 cr. Also, reported net profit for the period came in 95.8% below the estimate of Rs 11 cr.
Revenue for the quarter declined by 26.8% yoy to Rs 187.13 cr. Drop in revenue was mainly on account of 43.6% dip to Rs 137.25 in revenues from Europe, UK business as compared to H1FY16.

EBITDA declined by 87.4% yoy to Rs 6.47 cr while EBITDA margins dipped 1,665 bps yoy to 3.5%. Fall is because of operating expenses remaining flat yoy even though there is fall in revenues of 26.8% yoy.

Net profit dropped by 98.66% yoy to Rs 0.48 cr. However, finance cost has decreased 63% yoy. 
Technical View:

Marksans Pharma Ltd ended at Rs. 47.55, down by 1.5 points or 3.06% from its previous closing of Rs. 49.05 on the BSE.
The scrip opened at Rs. 49.1 and touched a high and low of Rs. 49.1 and Rs. 45.2 respectively. A total of 861325(NSE+BSE) shares were traded on the counter. The stock traded above its 50 DMA.

BSE 52.60 [0.80] ([1.50]%)
NSE 52.50 [1] ([1.87]%)

***Note: This is a NSE Chart



  • FREE Demat A/c + Rs.2000 Cashback ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.
welcome to iifl